TolerogenixX, a Germany-based clinical-stage biopharmaceutical company developing personalised cell therapies for antigen-specific immune tolerance, has received Orphan Drug Designation (ODD) from the European Commission for its lead investigational therapy, MIC-Lx, for use in living-donor kidney transplantation. The designation follows a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP).

The latest regulatory milestone comes shortly after MIC-Lx was granted EMA's PRIority MEdicines (PRIME) designation, further strengthening the therapy's regulatory pathway toward potential approval in Europe.

MIC-Lx is designed to address the unmet medical need in kidney transplantation, where patients typically require lifelong systemic immunosuppressive therapy to prevent organ rejection. While effective, long-term immunosuppression is associated with serious complications, including infections, malignancies, cardiovascular disease and chronic kidney damage.

Unlike conventional therapies, MIC-Lx is designed to induce donor-specific immune tolerance before transplantation, helping protect the transplanted organ while preserving the patient's overall immune function. The therapy is based on TolerogenixX's proprietary Modified Immune Cell (MIC) technology and aims to reduce dependence on lifelong immunosuppressive drugs while improving graft survival and long-term patient outcomes.

The European Commission's Orphan Drug Designation provides several regulatory and commercial incentives, including scientific protocol assistance from the EMA, reduced regulatory fees and, subject to marketing approval, up to 10 years of market exclusivity across the European Union.

MIC-Lx is currently being evaluated in the randomized, controlled Phase 2b TOL-2 clinical trial involving living-donor kidney transplant recipients. Following treatment of all 63 donor-recipient pairs, the study has entered its follow-up phase, with topline results expected in the first half of 2027.

The therapy has previously completed the Phase 1b TOL-1 trial, which demonstrated sustained safety and tolerability after a single administration while maintaining normal immune responses.

Beyond kidney transplantation, TolerogenixX is also exploring the potential of its MIC platform for autoimmune diseases, including systemic lupus erythematosus and multiple sclerosis. The company's manufacturing process enables personalized cell therapies to be produced within 24 hours using cells collected through leukapheresis, supporting scalable production for broader clinical use.